‘Sun Pharma open to taking more risks in R&D and investing more
Business Standard|November 03, 2022
India's largest drugmaker by market share, Sun Pharmaceutical Industries (Sun Pharma) has seen its specialty products pay off. It derives 32 per cent of its business from India, over 30 per cent of consolidated sales from the US. Its specialty portfolio grew 11 per cent YoY in the second quarter to $201 million. Its Chief Executive Officer of North America ABHAY GANDHI and group Chief Financial Officer CS MURALIDHARAN tell Sohini Das about their plans. 
Sohini Das
‘Sun Pharma open to taking more risks in R&D and investing more

Are patient footfalls at clinics back to pre-pandemic levels in the US?

Abhay: Footfalls at clinics in the US are still nowhere close to normal. But the number of medical representatives visiting doctors is back to pre-pandemic levels. It will take two to three months to get an appointment to visit a family physician.

How are you planning your US pipeline to beat price erosion?

Abhay: A lot of our research and development (R&D) is focused on generics. About 22 per cent of the overall R&D budget is for specialty. We are always looking into options for products that will have limited competition, exclusivity periods after launch. We are focused on complex generics. We drop six to eight products on an annual basis to be able to focus on bigger opportunities, so that the pipeline has a certain value. We rationalise our pipeline every year. We revisit portfolio every three months. A formal decision on the launch pipeline as a long-range plan is revisited once every year.

Is pricing pressure in the US easing somewhat?

هذه القصة مأخوذة من طبعة November 03, 2022 من Business Standard.

ابدأ النسخة التجريبية المجانية من Magzter GOLD لمدة 7 أيام للوصول إلى آلاف القصص المتميزة المنسقة وأكثر من 9,000 مجلة وصحيفة.

هذه القصة مأخوذة من طبعة November 03, 2022 من Business Standard.

ابدأ النسخة التجريبية المجانية من Magzter GOLD لمدة 7 أيام للوصول إلى آلاف القصص المتميزة المنسقة وأكثر من 9,000 مجلة وصحيفة.

المزيد من القصص من BUSINESS STANDARD مشاهدة الكل
KEEPING UP WITH BRAZIL
Business Standard

KEEPING UP WITH BRAZIL

If India wants to become a biofuel superpower like Brazil, it needs to get its ethanol 2.0 policies right

time-read
5 mins  |
January 08, 2025
Business Standard

Indian cities reduce PM2.5 levels by 27% in 6 yrs: Report

Indian cities achieved an average 27 per cent reduction in PM2.5 pollution levels from 2019 to 2024, with those under NCAP alone recording a 24 per cent decline, a new report has found.

time-read
1 min  |
January 08, 2025
India adding N-power faster than global peers
Business Standard

India adding N-power faster than global peers

India's nuclear power generation has grown twice as fast as the rest of the world in recent times.

time-read
2 mins  |
January 08, 2025
Manmohan Singh was unfailingly measured, thoughtful and wise
Business Standard

Manmohan Singh was unfailingly measured, thoughtful and wise

It is both an honour and pleasure to have been invited to address this event in honour of Dr Manmohan Singh, the greatest man I have had the privilege of knowing.

time-read
3 mins  |
January 08, 2025
Compare cited reasons with policy terms before challenging decision
Business Standard

Compare cited reasons with policy terms before challenging decision

Health and general insurers paid 82 per cent of claims by volume and 71.3 per cent by value (₹1.17 crore), according to the Insurance Regulatory and Development Authority of India's (Irdai's) annual report for 2023-24.

time-read
2 mins  |
January 08, 2025
PVR Inox shares fade to black: Down 23%
Business Standard

PVR Inox shares fade to black: Down 23%

Shares hit 44-month low as HMPV scare rattles market

time-read
3 mins  |
January 08, 2025
Indo Farm shares up 27% on mkt debut
Business Standard

Indo Farm shares up 27% on mkt debut

Shares of Indo Farm Equipment on Tuesday ended with a premium of over 27 per cent against the issue price of ₹215. The stock started the trade at ₹258.40, reflecting a premium of 20.18 per cent on the BSE. During the day, it jumped 33.44 per cent to ₹286.90. Shares of the firm ended at ₹272.70, up 26.83 per cent. At the NSE, it listed at ₹256, up 19 per cent. The stock ended at ₹273.69, a gain of 27.29 per cent. The company's market valuation stood at ₹1,310.37 crore.

time-read
1 min  |
January 08, 2025
Zomato shares fall 5% after Jefferies downgrade
Business Standard

Zomato shares fall 5% after Jefferies downgrade

Food aggregator Zomato's shares bled on Tuesday, as the stock plunged up to 5 per cent to hit an intraday low of ₹251.40 per share.

time-read
1 min  |
January 08, 2025
Q3 updates point to strong growth ahead for jewellery companies
Business Standard

Q3 updates point to strong growth ahead for jewellery companies

Two leading listed jewellers, Titan and Kalyan, have just released their pre-quarterly updates for the third quarter of the current financial year (Q3FY25).

time-read
2 mins  |
January 08, 2025
Equities may deliver 8-12% in 2025, says ABSL MF
Business Standard

Equities may deliver 8-12% in 2025, says ABSL MF

In a year that is poised to be one of macroeconomic turbulence, with significant policy shifts and global trade uncertainties, investors should consider asset allocation strategies to capitalize on gains in all asset classes while reducing risks, Aditya Birla Sun Life Mutual Fund (ABSL MF) said in its outlook for 2025.

time-read
1 min  |
January 08, 2025